Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome Prices IPO at 7.5 Euros per Share; Will Start Trading on Eurolist Tomorrow

NEW YORK, June 26 (GenomeWeb News) - OncoMethylome Sciences has priced its initial public offering at €7.50 ($9.44) per share and will begin trading on the Eurolist exchange in Brussels and Amsterdam tomorrow, the company said today.

 

The company said that it expects to raise €22 million ($27.7 million) by issuing 2,933,334 new shares. It could raise up to €25 million if a 15 percent over-allotment option is exercised in full.

 

Approximately 12 percent of the shares will be allocated to retail investors in Belgium and The Netherlands and the remaining shares will be allocated to institutional investors in Belgium, The Netherlands, and elsewhere in Europe.

 

OncoMethylome Sciences, which is developing diagnostics based on DNA methylation patterns, will be listed under the ticker symbol ONCOB by Euronext Brussels and under the ticker symbol ONCOA by Euronext Amsterdam.

 

The company is based in Liège, Belgium, and has a development team in Amsterdam.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.